- Home
- RPRX vs ACM Comparison
RPRX vs ACM Comparison
Compare RPRX & ACM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- ACM
- Stock Information
- Founded
- RPRX 1996
- ACM 1980
- Country
- RPRX United States
- ACM United States
- Employees
- RPRX N/A
- ACM N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- ACM Military/Government/Technical
- Sector
- RPRX Health Care
- ACM Consumer Discretionary
- Exchange
- RPRX Nasdaq
- ACM Nasdaq
- Market Cap
- RPRX 14.2B
- ACM 12.4B
- IPO Year
- RPRX 2020
- ACM 2007
- Fundamental
- Price
- RPRX $31.03
- ACM $88.97
- Analyst Decision
- RPRX Strong Buy
- ACM Strong Buy
- Analyst Count
- RPRX 5
- ACM 8
- Target Price
- RPRX $41.60
- ACM $120.38
- AVG Volume (30 Days)
- RPRX 4.7M
- ACM 1.0M
- Earning Date
- RPRX 05-08-2025
- ACM 05-05-2025
- Dividend Yield
- RPRX 2.77%
- ACM 1.12%
- EPS Growth
- RPRX N/A
- ACM 685.21
- EPS
- RPRX 1.91
- ACM 3.50
- Revenue
- RPRX $2,263,576,000.00
- ACM $16,219,730,000.00
- Revenue This Year
- RPRX $34.04
- ACM $6.71
- Revenue Next Year
- RPRX $6.10
- ACM $5.56
- P/E Ratio
- RPRX $16.63
- ACM $26.43
- Revenue Growth
- RPRX N/A
- ACM 8.89
- 52 Week Low
- RPRX $24.05
- ACM $82.23
- 52 Week High
- RPRX $34.20
- ACM $118.56
- Technical
- Relative Strength Index (RSI)
- RPRX 36.17
- ACM 33.26
- Support Level
- RPRX $30.82
- ACM $90.31
- Resistance Level
- RPRX $31.85
- ACM $95.96
- Average True Range (ATR)
- RPRX 0.76
- ACM 2.05
- MACD
- RPRX -0.25
- ACM -0.07
- Stochastic Oscillator
- RPRX 9.57
- ACM 10.27
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $14.4 billion in sales and $847 million in adjusted operating income in fiscal 2023.